Bavarian Nordic A/S

Report azionario CPSE:BAVA

Capitalizzazione di mercato: DKK 14.2b

Bavarian Nordic Crescita futura

Criteri Future verificati 1/6

Bavarian Nordic prevede che gli utili e i ricavi cresceranno rispettivamente di 3.1% e 2.6% all'anno. Si prevede che l'EPS diminuirà di 1.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 6.4% in 3 anni.

Informazioni chiave

3.1%

Tasso di crescita degli utili

-1.39%

Tasso di crescita dell'EPS

Biotechs crescita degli utili23.1%
Tasso di crescita dei ricavi2.6%
Rendimento futuro del capitale proprio6.35%
Copertura analitica

Low

Ultimo aggiornamento18 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento della narrazione • Jun 15

BAVA: Public Preparedness Contracts Will Support 2026 Earnings Upside

Analysts have kept their DKK 273.33 price target for Bavarian Nordic broadly unchanged, citing only minor adjustments to the discount rate, revenue growth assumptions and future P/E estimates in their valuation work. What's in the News Bavarian Nordic secured a government contract valued at over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine in 2026 and 2027, bringing Public Preparedness business contracts for 2026 to about DKK 2,200 million (Source: company announcement, recent news reports).
Aggiornamento della narrazione • Jun 01

BAVA: Public Preparedness Contracts And Vaccine Manufacturing Expansion Will Support 2026 Upside

Analysts have nudged their fair value estimate for Bavarian Nordic higher from DKK 268.33 to DKK 273.33. They point to adjusted assumptions around revenue growth, profit margins and future P/E as the main drivers of the updated price target.
Aggiornamento della narrazione • May 16

BAVA: Public Preparedness Contracts And Vaccine Approvals Will Support Higher Future Returns

Analysts have kept their DKK 280 price target for Bavarian Nordic unchanged, pointing to slightly higher assumed revenue growth and profit margins, along with a modestly higher discount rate and a lower future P/E expectation as key inputs behind the refreshed valuation work. What's in the News Bavarian Nordic raised its earnings guidance for 2026, now expecting revenue of DKK 5,500 million to DKK 5,700 million, compared with the earlier range of DKK 5,000 million to DKK 5,200 million.
Aggiornamento della narrazione • Apr 30

BAVA: Vaccine Approvals And Capacity Expansion Will Drive Future Upside

Analysts have kept their DKK 250.00 price target for Bavarian Nordic unchanged. They point to only small tweaks to assumptions on discount rate, revenue contraction, profit margin and future P/E, which they view as largely offsetting each other.
Aggiornamento della narrazione • Apr 16

BAVA: Expanded Vaccine Manufacturing Partnership Will Support 2026 Upside

Analysts have kept their DKK price target for Bavarian Nordic effectively unchanged, with a DKK 0.00 net move. Small tweaks to the discount rate and future P/E assumptions offset each other in their updated valuation work.
Aggiornamento della narrazione • Apr 01

BAVA: Expanded Vaccine Pipeline And New Contracts Will Support Higher Future Returns

Analysts have raised their price target on Bavarian Nordic from DKK 244.00 to DKK 280.00. They cite updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that they view as better reflecting the company’s current outlook.
Aggiornamento della narrazione • Mar 18

BAVA: Expanded Vaccine Partnerships And 2026 Orders Will Support Upside

Analysts have raised their price target on Bavarian Nordic from DKK 265 to about DKK 268, reflecting adjustments to their valuation inputs, including a slightly higher discount rate, a modest change to revenue growth expectations and a marginally different assumed future P/E and profit margin profile. What's in the News Bavarian Nordic expanded its partnership with Serum Institute of India to include full tech transfer and contract manufacturing for the chikungunya vaccine CHIKV VLP, aiming to scale capacity for future supply to endemic low and middle income countries.
Aggiornamento della narrazione • Mar 04

BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside

Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.
Aggiornamento della narrazione • Feb 18

BAVA: Share Buybacks And Latin America Vaccine Deal Will Support Upside

Analysts now keep their DKK 250 price target for Bavarian Nordic intact, as slightly higher discount and future P/E assumptions together with a modestly stronger profit margin view offset softer revenue growth expectations. What's in the News Bavarian Nordic issued earnings guidance for fiscal 2026, indicating expected revenue in the range of DKK 5,000 million to DKK 5,200 million (Corporate guidance).
Aggiornamento della narrazione • Feb 03

BAVA: Latin America Vaccine Deal Will Support Future Earnings Upside

Analysts have nudged their price target on Bavarian Nordic higher to €265, up from €260, citing updated assumptions on discount rates, revenue expectations, profit margins and forward P/E multiples. What's in the News Bavarian Nordic signed an agreement with Eurofarma, giving Eurofarma exclusive rights to sell and distribute the chikungunya vaccine CHIKV VLP, marketed as VIMKUNYA, in Brazil, along with a right of first refusal for future Latin American opportunities, on a transfer price and royalty basis with no upfront or milestone payments (Key Developments).
Aggiornamento della narrazione • Jan 20

BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings

Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.
Aggiornamento della narrazione • Jan 06

BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside

Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.
Aggiornamento della narrazione • Dec 16

BAVA: Mpox Preparedness Contracts Will Underpin Stronger Long Term Earnings Power

Analysts have raised their price target on Bavarian Nordic from approximately $225 to about $250. This reflects a higher justified valuation multiple despite expectations for softer revenue growth and margins.
Aggiornamento della narrazione • Dec 02

BAVA: Procurement Agreement And Margin Outlook Signal Upside For Shares

Analysts have raised their price target for Bavarian Nordic from €250 to €260. They cite improvements in projected profit margins and lower expected future price-to-earnings ratios, even though there is a modest increase in the discount rate and a slightly weaker revenue growth outlook.
Aggiornamento della narrazione • Oct 24

Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins

Narrative Update on Bavarian Nordic Analysts have raised their fair value price target for Bavarian Nordic from €244 to €250, citing modest improvements in valuation assumptions and financial projections. What's in the News Officials in California have confirmed community spread of the new clade 1 Mpox strain among residents with no recent international travel.
Aggiornamento della narrazione • Aug 27

VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues

Despite a deterioration in consensus revenue growth forecasts, a modest improvement in net profit margin has supported a slight increase in Bavarian Nordic's fair value, with the target price rising from DKK234.50 to DKK244.00. What's in the News Nordic Capital and Permira have proposed to acquire Bavarian Nordic for DKK 18.1 billion (DKK 233 per share), a 21% premium to the prior closing price; board and management have agreed to tender their shares, and a delisting is planned upon completion, subject to customary conditions.
Articolo di analisi • Jul 28

Bavarian Nordic A/S (CPH:BAVA) Held Back By Insufficient Growth Even After Shares Climb 38%

Despite an already strong run, Bavarian Nordic A/S ( CPH:BAVA ) shares have been powering on, with a gain of 38% in the...
Articolo di analisi • Jun 13

Earnings Working Against Bavarian Nordic A/S' (CPH:BAVA) Share Price

When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
Articolo di analisi • Apr 03

Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet

Key Insights Bavarian Nordic's Annual General Meeting to take place on 9th of April Total pay for CEO Paul Chaplin...
Articolo di analisi • Mar 13

Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear

The market for Bavarian Nordic A/S' ( CPH:BAVA ) shares didn't move much after it posted weak earnings recently. We...
Articolo di analisi • Mar 08

Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Bavarian Nordic A/S ( CPH:BAVA ) came out with its yearly results last week, and we wanted to see how the business is...
User avatar
Nuova narrazione • Feb 10

Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks

The chikungunya vaccine launch and expansion into new markets could significantly drive revenue and broaden customer base.
Articolo di analisi • Dec 14

Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely

With a median price-to-earnings (or "P/E") ratio of close to 14x in Denmark, you could be forgiven for feeling...
Articolo di analisi • Nov 16

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Articolo di analisi • Aug 26

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S ( CPH:BAVA ) shareholders have had their patience rewarded with a 53% share price jump in the last...
Articolo di analisi • Aug 25

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Last week, you might have seen that Bavarian Nordic A/S ( CPH:BAVA ) released its quarterly result to the market. The...

Previsioni di crescita degli utili e dei ricavi

CPSE:BAVA - Stime future degli analisti e dati finanziari passati (DKK Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20286,0279421,3091,4654
12/31/20275,6467521,3241,6104
12/31/20265,6537271,4001,8963
3/31/20265,9551,1741,3072,357N/A
12/31/20256,2441,3751,3632,722N/A
9/30/20256,8872,4451,2843,132N/A
6/30/20256,4551,423-4341,767N/A
3/31/20256,2311,321-9211,128N/A
12/31/20245,7169882621,950N/A
9/30/20246,0701,1192791,580N/A
6/30/20246,0837078821,958N/A
3/31/20246,6429841,0281,769N/A
12/31/20237,0621,4751421,119N/A
9/30/20235,906723-793751N/A
6/30/20235,5331,076-979568N/A
3/31/20234,083301-1,344-18N/A
12/31/20223,151-347-1,162220N/A
9/30/20222,404-599-1,345-109N/A
6/30/20221,849-693-1,342-101N/A
3/31/20221,683-606-1,477-215N/A
12/31/20211,898-465-1,417-358N/A
9/30/20211,583-737-1,541-663N/A
6/30/20211,693-629-1,279-478N/A
3/31/20212,022-368-72720N/A
12/31/20201,852278-135572N/A
9/30/20201,914606-1,613981N/A
6/30/20201,499481-1,970623N/A
3/31/2020901267-2,427227N/A
12/31/2019662-347N/A-276N/A
9/30/2019554-402N/A-262N/A
6/30/2019631-271N/A-204N/A
3/31/2019616-279N/A-152N/A
12/31/2018501-362N/A-289N/A
9/30/2018360-445N/A-467N/A
6/30/2018873-151N/A-564N/A
3/31/20181,1845N/A-158N/A
12/31/20171,370181N/A216N/A
9/30/20171,745453N/A1,030N/A
6/30/20171,463225N/A880N/A
3/31/20171,182153N/A501N/A
12/31/20161,00731N/A268N/A
9/30/2016909-54N/A-539N/A
6/30/2016536-202N/A-345N/A
3/31/2016808-115N/A-561N/A
12/31/20151,02159N/A105N/A
9/30/20151,244155N/A818N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di BAVA ( 3.1% all'anno) è superiore al tasso di risparmio ( 2% ).

Guadagni vs Mercato: Si prevede che gli utili di BAVA ( 3.1% all'anno) cresceranno più lentamente rispetto al mercato Danish ( 7.6% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di BAVA cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di BAVA ( 2.6% all'anno) crescerà più lentamente rispetto al mercato Danish ( 4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di BAVA ( 2.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di BAVA sarà basso tra 3 anni ( 6.4 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/01 08:05
Prezzo dell'azione a fine giornata2026/07/01 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Bavarian Nordic A/S è coperta da 13 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jacob LademannCarnegie Investment Bank AB
Peter VerdultCitigroup Inc
Hakon Hemme JørgensenDanske Bank